Olutasidenib for Acute Myeloid Leukemia

This trial tests a medication called olutasidenib for individuals with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a specific IDH1 mutation. The goal is to assess patient response to this treatment after previous therapy, including venetoclax, ceased to be effective. Participants take olutasidenib pills daily in 28-day cycles and may later add azacitidine if needed. This trial suits those who have tried up to two lines of treatment and have AML with the IDH1 mutation. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.

You may need to stop taking certain medications before joining the trial. Specifically, if you are using strong or moderate CYP3A inducers or sensitive CYP3A substrates, you must stop them at least 2 weeks or 5 half-lives (whichever is longer) before starting the trial treatment.

Previous studies have shown that olutasidenib is safe and manageable for treating acute myeloid leukemia (AML) with the IDH1 gene mutation. Over five years, patients using olutasidenib did not experience any new serious side effects compared to earlier results. This consistency suggests the treatment is well-tolerated over time. Additionally, the FDA has already approved olutasidenib for this condition, supporting its safety in humans. Overall, research indicates that olutasidenib is generally safe for those with relapsed or refractory AML with the IDH1 mutation.¹²³⁴⁵

Olutasidenib is unique because it targets a specific mutation in the IDH1 gene, which is not addressed by most standard treatments for Acute Myeloid Leukemia (AML). Traditional AML treatments often involve chemotherapy drugs like cytarabine and daunorubicin, which generally target rapidly dividing cells. In contrast, Olutasidenib works by inhibiting the mutant IDH1 enzyme, potentially stopping the cancer from growing and spreading. Researchers are excited about Olutasidenib because this targeted approach could offer a more effective treatment option with fewer side effects for patients with this specific genetic mutation.

Research has shown that olutasidenib can help treat acute myeloid leukemia (AML) in patients with an IDH1 mutation. Studies indicate that about 48% of patients responded to the treatment, with nearly half experiencing positive effects. Additionally, around 35% of patients achieved complete remission, where the cancer becomes undetectable, after using olutasidenib. In this trial, participants will receive olutasidenib, and azacitidine may be added after three cycles if needed. This suggests that olutasidenib could be a promising option for those whose AML has returned or is resistant to other treatments.¹²⁶⁷⁸